CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants
CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variantsCP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience ...
